[go: up one dir, main page]

EP0424044A1 - Poule transgénique exprimant l'hormone de croissance bovine - Google Patents

Poule transgénique exprimant l'hormone de croissance bovine Download PDF

Info

Publication number
EP0424044A1
EP0424044A1 EP90311209A EP90311209A EP0424044A1 EP 0424044 A1 EP0424044 A1 EP 0424044A1 EP 90311209 A EP90311209 A EP 90311209A EP 90311209 A EP90311209 A EP 90311209A EP 0424044 A1 EP0424044 A1 EP 0424044A1
Authority
EP
European Patent Office
Prior art keywords
gene
growth hormone
vector
bovine growth
fowl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90311209A
Other languages
German (de)
English (en)
Inventor
Howard Y. Chen
Ellen A. Garber
John J. Kopchick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0424044A1 publication Critical patent/EP0424044A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • Desired traits and the life are used herein to refer to phenotypic characteristics providing a distinct commercial advantage in the animal undergoing selection.
  • the possibilities for enhancing desirable animal traits range from inducing more efficient growth and feeding characteristics to enhanced disease resistance. Selective animal breeding is slow, labor intensive, and often does not result in the selection of a given desirable trait.
  • avian retroviruses as vectors to introduce foreign genes into the day one avian egg. Their infectivity allows exposure of a foreign gene of interest to many cells, including germline cells.
  • Crittendon et al. reported that one of the chickens that emerged from an egg infected with ALV subgroup A (containing no foreign gene), was observed to be non-viremic, presumably due to deletion of required viral replicative or infective functions. When this bird was challenged with infection by ALV, the chicken was fortuitously found to be resistant. However, the strongly undesirable increased incidence of bursal lymphoma development in progeny homozygous or heterozygous for the integrated sequences was noted.
  • the term "reactive expression” will be used herein to denote more than the process of an animals' generation of a given gene product, as such production of a given protein may or may not generate a transgenic with a desirable characteristic. This term is used to define a transgenic that in fact develops a phenotype improved by the expression of the given foreign gene.
  • the term "avian” is intended to include the various known strains of Gallus gallus, or chickens, (e.g. white leghorn, brown leghorns, London, New Hampshire, Rhode Island, Ausstralorp, Minorca, Amrox, California gray, Italian partridge-colored), as well as turkeys, pheasants, quail, duck, and other poultry commonly bred in commercial quantities. This breadth is justified in that the A strain of RSV is known to infect chickens, turkeys, pheasants, red jungle fowl.
  • the retroviral vectors of the instant invention have the additional advantages of stability, absence of oncogenic sequences, and high infectivity to the target tissues of interest. These and other advantages facilitate production of transgenic fowl useful in the poultry industry for breeding better chickens, turkeys, and other avian animals.
  • the present invention is a substantial step forward in the quest for a retroviral vector delivery system for the production of transgenic fowl.
  • the disclosed invention relates to the production of transgenic fowl carrying and expressing the bovine growth hormone gene.
  • Replication competent and replication defective retroviral vectors have been constructed that allow expression of foreign genes in vitro and in vivo.
  • the bovine growth hormone and the firefly luciferase genes were stably incorporated into cultured avian cells and functional gene products were expressed.
  • a retroviral vector derived from the Schmidt-Ruppin A strain of Rous Sarcoma Virus (SRA-RSV) carrying the bovine growth hormone gene under transcriptional regulation of the mouse metallothionein promoter has been introduced into the developing chicken embryo.
  • the SRA-RSV pol gene was replaced by the Bryan High titer polymerase gene to enable the production in vitro of a high titer stock of the viral vector for infection of the avian egg without loss of the bovine growth hormone gene.
  • Oncogenic sequences were removed and allowed insertion of the bGH gene along with the zinc inducible metallothionein promoter.
  • transgenic birds were derived which had detectable levels of circulating bovine growth hormone.
  • clone cells in a cell line or nucleic acid molecules which are genetically identical.
  • foreign gene a gene not normally found in the genome of a given virus, cell or organism.
  • gene a piece of genetic material, DNA or RNA, which encodes information for a specific protein.
  • genome the total genetic material composed of DNA or RNA of an organism, cell, or virus.
  • homologous recombination the mechanism proposed for the observation that genetic elements having sequence homology may rearrange themselves in a biological system, incorporating segments of the original nucleic acids to yield a new genetic element.
  • insert a piece of genetic material that may be joined with another piece of genetic material integration: the process whereby a segment of DNA becomes joined with the chromosome of a live organism or cell.
  • integration the process whereby sequences from one source become incorporated into the genome of a cell or organism.
  • ligation the process of joining two DNA sequences with matching restriction sites with the enzyme DNA ligase.
  • nonpermuted virus the order of sequences in a particular virus or vector as found in the original retrovirus in nature, e.g., gag , pol , env without interruption by sequences extraneous to these genes.
  • oncogenic sequences genes which have been discovered to encode functions that are capable of transforming cells to an oncogenic state.
  • phenotype the gross appearance, behavior or capabilities of an organism that are the observable expression of underlying genetic characteristics, e.g., eye color.
  • proviral DNA the deoxyribonucleic acid molecule produced as a result of reverse transcription of the ribonucleic acid genome of a retrovirus; the proviral DNA often undergoes rearrangements and duplication of sequences present in the RNA genome, and is capable of integration into the DNA genome of its host.
  • reactive expression the process whereby a given gene is expressed in an cell, organism. or animal, and in which such expression yields a positive influence on the phenotype of said cell, organism, or animal.
  • receptor a protein usually localized in the outer membrane of a cell that recognizes a specific ligand with high affinity.
  • replication the process whereby a genome is duplicated by DNA polymerase or RNA polymerase.
  • restriction enzyme an enzyme capable of recognizing a specific local sequence of bases in a DNA duplex and producing a double strand scission at that location; the cut site of the enzyme is convenient for joining pieces of DNA with like cut sites.
  • retrovirus an obligate intracellular parasite whose RNA genome is reverse transcribed into a DNA sequence once infection of a host cell has occurred, and may become integrated into the host cell genome as a provirus.
  • reverse transcriptase the enzyme encoded by the retroviral pol gene responsible for generation of a proviral DNA copy of the retroviral RNA genome.
  • transfection the technique for introducing nucleic acid molecules, usually of viral origin, into a cell such that the cell becomes infected subsequently produces virus.
  • transformation the technique for introducing a plasmid into a bacterial cell; also the description of a cell that has become neoplastic.
  • transgenic animal an animal carrying in its chromosomal material sequences from a foreign chromosome.
  • vector a piece of DNA, often in a circular conformation, capable of replication in an appropriate organism or cell and capable of accepting additional DNA sequences.
  • ALV avian leukosis virus
  • bGH bovine growth hormone
  • BGHMT the bovine growth hormone gene under transcriptional regulation of the mouse metallothionein promoter
  • cDNA complementary DNA copy of a messenger RNA
  • CEF chicken embryo fibroblasts
  • cGH chicken growth hormone
  • env the envelope gene of the retrovirus
  • gag the retroviral group-specific antigen
  • REV Reticuloendotheliosis virus
  • RSV Rous Sarcoma Virus
  • This invention relates to retroviral vectors for the production of transgenic fowl.
  • This technology overcomes the inaccessibility of the avian embryo which has to date limited the success of genetic manipulation of the avian genome.
  • the invention relies on unique features of retroviral physiology, it will be profitable to briefly review the salient features of the retroviral life cycle.
  • a retrovirus is an obligate intracellular parasite composed of an envelope protein defining its host specificity ( env ), a group-specific core antigen ( gag ), and a reverse transcriptase enzyme ( pol ).
  • the gene product is responsible for generating a DNA copy of the RNA genome enclosed within the viral particle composed of the elements described above.
  • the virus Upon 'docking' of the viral env protein with a receptor present on the surface of a host's cell, the virus penetrates into the cell and the RNA dependent DNA polymerase begins reverse transcription of the viral RNA.
  • the resulting proviral DNA copy inserts itself into the host cell genome and is replicated along with the cell's other genetic material during cell division.
  • the viral proteins are produced as a result of the cellular machinery transcribing integrated viral DNA sequences into messenger RNA which is then translated by the cell into new copies of gag , env , and pol . Some of the RNA is incorporated into new viral particles which then bud from the cell to begin a new round of infection.
  • retroviruses Due to their physiology, retroviruses are in many ways ideally suited to the task of ferrying foreign genes into eukaryotic genomes. They are highly infectious in culture, usually transfecting 100% of a population of cells. They are small and therefore readily manipulated in vitro, and essential functions for the encoded genes have been elucidated.
  • retroviral vectors for introduction of foreign genes has a number of drawbacks. Namely, many naturally occurring retroviruses encode oncogenic sequences, for example src in the rous sarcoma virus. It is therefore necessary to eliminate these undesirable sequences. In fact a useful gene might be inserted in place of the removed oncogenic sequences.
  • Retroviruses are inherently unstable. They have become adept at integrating themselves into the genomes of their hosts, sometimes picking up new sequences, sometimes losing sequences. Many higher eukaryotic genomes are loaded with retroviral sequences integrated in the form of the DNA proviral copy of the viruse's RNA genome. The presence of these genomic proviral copies of the retrovirus in part contributes to the instability of retroviral vectors due to homologous recombination.
  • the retroviral promoters are encompassed by the long terminal repeats (LTR's), so named because of the identical sequences occurring at either end of the provirus during the DNA phase of its life cycle.
  • LTR's long terminal repeats
  • the identity of these sequences exacerbates the problems of homologous recombination.
  • the LTR's are also such powerful enhancers of gene transcription, they have the added shortcoming of being capable of activating host oncogenic sequences.
  • a solution to these problems may lie in the use of weaker promoters incapable of activating undesirable gene products, and in replacing regions of high homology to edogenous proviruses with sequences of less homology having similar functionality.
  • An ideal vector would be highly infectious to the target tissue of interest, but should be limited to a single round of infection such that a viremic animal is not produced.
  • the use of such replication defective vectors has been described in other retroviral delivery systems.
  • Such vectors are deleted for one or more of the genes necessary for multiple rounds of infection.
  • This system however requires the use of a helper cell [Temin et al. US 4,650,764 (1987)] to generate a high titer viral stock for an initial infection.
  • Attendant with this technology is the increased probability of rearrangements including deletion of the desired exogenous gene during passage through the helper cell line. This shortcoming is being addressd, and helper cell lines are emerging in which the incidence of deletions and rearrangements due to homologous recombination is greatly attenuated.
  • the vector should contain no oncogenic sequences, and should be modified so as to be ineffective in the activation of undesirable genomic sequences.
  • the vector should insert itself into a known predetermined location in the host chromosome so as to be in a transcriptionally active context, while in no way interrupting host gene functions [Dorin et al., Science 243 : 1357-1360 (1989)].
  • the vector should be capable of stably introducing a desired expressible gene into the host chromosome to allow the production of the desired effect in the animal under study.
  • the state of the art has as yet not met all of these criteria, but rapid advances are being made.
  • the instant invention is a significant step forward in the quest for a retroviral vector delivery system for production of transgenic fowl.
  • retroviruses have been identified that have adapted themselves to different avian hosts (Hughes et al., Virology 108 : 222-229 (1981); Gudkov et al., J. Gen. Virol. 57 : 85-94 (1981)).
  • the genomes of these viruses are constructed along similar functional motifs (see fig. 1).
  • LTR long terminal repeat
  • a linear sequence one encounters from left to right, a long terminal repeat (LTR) comprising viral replication control elements (promoter, enhancer, integration functions), the structural gene coding region ( gag , pol , env ), an oncogenic sequence such as src (not always present), followed by the right hand LTR.
  • LTR long terminal repeat
  • retroviral sequences identified to date have similar restriction enzyme maps.
  • the procedure for preparing a functional retroviral vector requires the formation of a proviral DNA copy of the RNA, and subsequent modification of the DNA using standard molecular biology techniques (digestion with appropriate restriction enzymes, ligation of sequences of interest, etc. Maniatis et al. "Molecular Cloning: A Laboratory Manual.” Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). In general, it is convenient to replace unwanted oncogenic sequences with desirable sequences such as a foreign gene and a transcriptional promoter. It is also suggested that different host specificity may be conferred upon the vector due to the nature of the env gene product. Manipulations have been described in which such modifications have been performed resulting in infection of a foreign cell type by retroviruses derived from another species. In performing these manipulations, it is important not to damage any of the essential viral replication functions unless a replication defective vector is desired (Temin, U.S. 4,650,764)).
  • replication competent vectors are simpler to use as they require no additional helper functions, and the ongoing infection they produce obviates the necessity for the presence of a marker gene.
  • transgenic fowl generated by the use of a replication competent vector will be viremic and thus not suitable for commercialization.
  • Replication defective vectors have been described in the art [Bosselman et al. J. of Virol. 63 : 2680-2689 (1989); Bosselman et al. Science 243 : 533-535 (1989)]. These vectors code for a defective retroviral protein, usually the env gene product, such that the virus requires provision of the defective protein in trans. The production of a high titer stock of such a replication defective recombinant retrovirus thus requires culturing in a cell line that expresses the missing protein. The production of appropriate helper cells is the subject of U.S. patent # 4,650,764 of Temin.
  • the infection of a developing avian embryo with a high titer stock of a replication defective recombinant retrovirus requires infection of as many of the embryonic avian cells as possible upon initial exposure as no additional virus will be generated thereafter. In this case it becomes critical that a high titer stock of recombinant retrovirus carrying the desired foreign gene be used.
  • RNA of the Schmidt-Ruppin A strain of the avian Rous Sarcoma retrovirus may be reverse transcribed with reverse transcriptase to form a DNA copy of the viral genome.
  • appropriate linkers may be ligated onto the ends of the DNA, and large amounts of the proviral DNA generated by cloning into a vector carrying an E. coli origin of replication (for example pBR322). Appropriate deletions, additions and substitutions may then be performed and the resultant proviral DNA used for introduction into tissue culture cells to produce a high titer of infective virus for introduction into the avian germline.
  • Removal of src may be accomplished by digestion of the proviral DNA, generation of an acceptable cloning site by linker ligation, insertion of a desired sequence with compatible ends, and repair of any deleted essential replication sequences.
  • Desirable sequences such as a growth hormone gene, might confer enhanced growth characteristics, whereas expression of interferon induced proteins such as the murine MX protein [Horisberger et al. P.N.A.S. U.S.A. 80 : 1910-1914 (1983); Haller et al. WO87/00864: (Feb. 12, 1987)] or of pathogenic viral genes, for example the Newcastle disease virus hemagglutinin- neuraminidase gene, might confer enhanced disease resistance.
  • promoters of transcription are known in the art, the most commonly utilized of which is the zinc-inducible mouse metallothionein promoter.
  • constitutive promoters whose use has been reported include the SV40 early promoter, the phosphoenolpyruvate carboxykinase promoter, cytomegalovirus immediate early promoter, and the chicken actin gene promoter.
  • BH pol By replacing the pol gene of RSV with the gene encoding the Bryan High-titer polymerase (BH pol ), preparation of a high titer viral stock with a minimal amount of in vitro replication and manipulation is facilitated. In addition, a viral stock with the requisite titer may be generated, as a result of this replacement, in roughly half the time required compared with a vector encoding a low titer polymerase. These modifications thus minimize recombination and deletion of inserted sequences.
  • BH pol Bryan High-titer polymerase
  • At least five different subclasses of virus have been assigned on the basis of susceptibility of cells from given fowl to infection by the virus: A, B, C, D, E.
  • This specificity occurs as a result of either the presence or absence on the avian cell surface of receptors for the protein of the infecting virus.
  • the species specificity of the vector may thus be modified by replacement of the env gene with an env gene from a homologous retrovirus that infects the desired species [Dorner et al., J. Virol. 53 : 32-39 (1985); Bova et al., Virology 152 : 343-354 (1986); Kornbluth et al., Mol. Cell Biol.
  • the applicants utilized the calcium phosphate method of Cross et al. [Cell 34 :597-607 (1983)] to transfect and culture primary or secondary chicken embryo fibroblasts and found that in one of the preferred embodiments of the retroviral vector (pNPBGH85) that a high titer viral stock could be generated in five days.
  • retroviral vector pNPBGH85
  • quail cells in continuous culture were used to advantage according to Moscovici et al. [Cell 11 : 95-103 (1977)].
  • Retroviruses will delete foreign sequences during in vitro passage designed to generate the high titer infective stock.
  • the recognition that replacement of the low titer polymerase with a high titer polymerase gene, in addition to deletion of the upstream direct repeat, would contribute to overcoming this shortcoming is not obvious, but we report here that it is one of the possible solutions to this problem.
  • the culture supernatant may be titered for viral stock concentration by a number of methods.
  • a p27 ELISA may be used to calculate the concentration of viral envelope proteins in culture directly and thus to determine the viral concentration.
  • a volume of 100 microliters of a stock of 107 infectious units per milliliter represents 106 infectious units. Since the day one avian embryo consists of between 104 and 5x10 cells, introduction of 106 infectious viral particles means that whether or not a replication competent vector is used, every cell of the developing blastoderm, including the germ-line cells, will stand an excellent chance of undergoing infection by this initial viral assault.
  • a volume of virus between 10 and 500 microliters, depending on the viral stock concentration is injected into the egg just below the blastoderm.
  • the hole is wiped with an ethanol swab and resealed with wax.
  • the egg is then incubated under conditions kown in the art to promote development of the avian egg to term.
  • the vector, pNPBGH85 was used to transform E. coli DH5 and the culture given the name MB5436. This culture was deposited under the Budapest Treaty with the ATCC on October 4, 1989 and given ATCC accession number 68106.
  • Another vector, pNPRAV was used to transform E. coli DH5 and the culture given the name MB5437. This culture was deposited under the Budapest Treaty with the ATCC on October 4, 1989, and given ATCC accession number 68107.
  • the ATCC addresses is: 12301 Parklawn Dr., Rockville, MD 20852.
  • pSRBGH85 was digested to completion with Xho I. The reaction was heat-inactivated and diluted to a DNA concentration of 100 ng/ml. Ligated DNA was used to transform E . coli DH5 to ampicillin resistance. One of the resultant clones, pSRBGH85XD, was deleted for the 4.5 kilobase Xho I fragment.
  • Step II Transfection of Chicken Embryo Fibroblasts and Virus Preparation:
  • CEF's chicken embryo fibroblasts
  • a replication defective vector for producing nonviremic chickens expressing the bovine growth hormone gene is produced by construction of a vector that is deleted for the env gene such that no viral particles can be made inside a cell unless the cell provides the missing env gene product.
  • the construction of such a replication defective vector may be performed in several steps as follows:
  • Step A
  • Step B
  • Step C
  • Step D Preparation of pNPBGHdef:
  • E. coli is transformed with ligated DNA and a clone carrying a plamid with the desired structure, pNPBGHdef, obtained.
  • the vector is comprised of LTR- gag -BH pol -BGHMT-LTR sequences, similar to the genome of defective Bryan RSV, with the bGH gene replacing the gene. This vector is expected to generate transformed chicken embryo fibroblasts, and whole fowl, expressing bGH at the same levels obtained for pNPBGH85 (examples 5 and 6).
  • pNPBGHdef In order to utilize the replication defective vector, pNPBGHdef of example 2, it is necessary to transfect cells in culture, and produce, thereby, a viral stock. As pNPBGHdef is missing a functional env gene, the envelope protein must be provided in trans. This may be accomplished by transfecting a cell previously engineered to produce envelope glycoprotein [Temin et al. U.S. 4,650,764 (1987)]. Alternatively, a cell may be co-transfected with a vector that carries a functional env gene, such that the pNPBGH85 RNA is packaged into the pNPRAV env gene product. Construction of a helper virus vector, pNPRAV, was performed as follows:
  • Step A Preparation of pSRXDC1a :
  • the subgroupA Schmidt-Ruppin RSV derived vector p779/989-1089/2795 [Hughes and Kosik, Virology 136 : 89-99 (9184)] was digested to completion with Xhol.
  • the reaction mixture was heat-inactivated and diluted to a DNA concentration of 100 ng/ml.
  • DNA was ligated and used to transform E. coli DH5 to ampicillin resistance.
  • One resultant clone , pSRXDC1a was found to have deleted the 4.5 kilobasepair Xho1 fragment.
  • pSRXDC1a contains a unique Cla1 cloning site into which foreign genes can be inserted. Such inserts reside in the position that the removed src gene usually occupies in the RSV genome.
  • pSRXDC1a was digested to completion with Sal1 and EcoRV, and the 2.9 kilobasepair Sal1 fragment containing the retroviral sequences was isolated. This fragment was ligated to Sal1 linearized and phosphatase treated pSR-pol-beta [Sudol et al. Nuc. Acids Res. 14 : 2391-2405, (1986)]. Ligated DNA was used to transform DH5 E. coli to ampicillin resistance.
  • One resultant clone, pNPRAV was found to have the desired structure, comprising the nonpermuted proviral DNA of an avian leukosis virus LTR-gag-pol-env-LTR. Upon transfection into chicken embryo fibroblasts, pNPRAV produces infectious replication-competent virus, and can be used as a helper to complement a replication-defective virus.
  • the vector pNPBGH85 was prepared as described supra.
  • pNPRAV a plasmid which produces a replication competent helper virus was prepared in a multistep procedure analogous to that used for the production of pNPBGH85 but with no inserted foreign gene (example 2).
  • Secondary chicken embryo fibroblasts were transfected by calcium phosphate precipitation as described (example 1), using either no DNA, pNPRAV, or pNPBGH85. Transfected cultures were passaged every three to five days for a total of 25 days. Every five days, cell-free supernatant was harvested from confluent cultures and assayed for bovine growth hormone by radioimmunoassay. Genomic DNA was prepared from parallel transfected cultures.
  • bovine growth hormone was specific to pNPBGH85-transfected cells and was stable during long-term culture of fully infected cells.
  • DNA dot blot analysis of genomic DNA verified the presence of bovine growth hormone sequences (using a bovine growth hormone-specific probe derived from pBGH-10) and integrated provirus (using an exogenous LTR specific probe).
  • Presence of virus in culture fluid was verified by p27 gag ELISA analysis of cell lysates of fresh chicken embryo fibroblasts infected with virus harvested from transfected cells.
  • Virus titer was determined by endpoint dilution titration and p27 gag ELISA. TABLE I Average Bovine Growth Hormone Concentration (Duplicate Samples) bGH Concentration, ng/ml Days post Transfection: 5 10 15 20 25 DNA Transfected: None 3.8 4.9 5.7 2.1 4.5 pNPRAV 3.6 5.7 4.0 2.2 4.4 pNPBGH85 149.6 227.0 179.0 182.8 183.5
  • the methodology utilized for the construction of pNPBGH85 and pNPBGHdef may be generalized for the construction of avian retroviral vectors carrying other foreign genes.
  • This example describes the construction of pNPluc and pNPlucdef, replication competent and replication defective vectors respectively, carrying the firefly luciferase gene.
  • pSRXDC1a (see example 4 supra) was digested to completion with the Cla1 restriction enzyme, blunt ended, and treated with phosphatase.
  • Ligated DNA was used to transform E. coli DH5 and a clone with the desired structure, pSRlucd, was isolated.
  • the luciferase cDNA is in the same transciptional orientation as the retroviral structural genes in this construct.
  • Step B Preparation of pNPluc :
  • pSRlucd was digested to completion with Sal1 and BglI and the 4.7 kilobasepair SalI fragment containing the retroviral sequences was purified. This fragment was ligated to the phosphatase treated 10 kilobasepair pSR-pol-beta Sal1 fragement. Ligated DNA was used to transform E. coli DH5, and a clone isolated, pNPluc, having the desired structure: a nonpermuted proviral sequence with the luciferase gene replacing src . Expression of the luciferase gene in this vector is mediated by the viral transcriptional control signals, ie. the LTR promoter, the gag splice donor site, src acceptor site, and 3′ polyadenylation signal.
  • the viral transcriptional control signals ie. the LTR promoter, the gag splice donor site, src acceptor site, and 3′ polyadenylation signal.
  • Step II Construction of a Replication Defective Luciferase Vector, pNPlucdef:
  • a replication defective luciferase vector lacking envelope coding sequences was constructed by a three part ligation of the following DNA fragments:
  • luciferase vector constructs To assay the biological activity of the luciferase vector constructs, secondary chicken embryo fibroblasts were transfected with plasmid DNA as previously described (see example 1 supra). Transfected cells produced virus with the predicted proviral structures, as analyzed by Southern blot hybridization using either luciferase or LTR-specific probes. Cell lysates were prepared and analyzed for luciferase activity as described [DeWet et al. Mol. Cell. Biol. 7 : 725-737 (1987)]. Both pNPluc and pNPlucdef (when cotransfected with pNPRAV) produce virus carrying the luciferase gene, and both produce equivalent amounts of luciferase activity.
  • Fertilized eggs from Hubbard Leghorn line 139 chickens were collected immediately after laying and stored with the large-end up at 15 o C until use. A small portion of the egg shell (5 mm by 5 mm) was removed from the top without disturbing the inner membrane. After localizing the blastoderm, 50 ul volumes of virus stock, titered at 107 infectious units per milliliter, were injected in the immediate area of the blastoderm using a 27 gauge needle connected to a micropipet. Following this manipulation, the opening in the shell was covered with cellophane tape and sealed with paraffin. Eggs were incubated at 38 o C for further development. After hatching the chickens, meconium samples were taken for detecting virus by p27 ELISA.
  • Vectors carrying the subgroup-A env gene may be restricted in to infection of hosts expressing the subtype-A receptor on their cellular surface.
  • vector construction due to the homology of avian retroviral genomes, it is possible to remove a restriction fragment from a given env gene subtype and replace it with a restriction fragment from another viral subtype env gene and thereby confer a new host specificity on the vector.
  • Step 1
  • pSR pol -beta is digested to completion with Kpnl and Sall, and the 9 kilobase fragment is isolated.
  • Step 2
  • Step 3
  • Step 1 Ligate the fragment from step 1 with either the fragment from step 2a or step 2b to obtain a vector with a subgroup B or D env gene respectively.
  • the ligation mixture is used to transform E. coli and a clone with the desired substitution in env is selected.
  • helper with no foreign gene but encoding a functional gene product with the desired subgroup would provide the same specificity as the vectors described in this example.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP90311209A 1989-10-16 1990-10-12 Poule transgénique exprimant l'hormone de croissance bovine Withdrawn EP0424044A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42188189A 1989-10-16 1989-10-16
US421881 1989-10-16

Publications (1)

Publication Number Publication Date
EP0424044A1 true EP0424044A1 (fr) 1991-04-24

Family

ID=23672442

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90311209A Withdrawn EP0424044A1 (fr) 1989-10-16 1990-10-12 Poule transgénique exprimant l'hormone de croissance bovine

Country Status (3)

Country Link
EP (1) EP0424044A1 (fr)
JP (1) JPH03210136A (fr)
CA (1) CA2027619A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698763A (en) * 1991-11-14 1997-12-16 Weissmann; Charles Transgenic animals lacking prion proteins
WO2000075300A3 (fr) * 1999-06-04 2002-01-10 Tranxenogen Inc Procedes servant a manipuler le genome aviaire
WO2004016081A1 (fr) * 2002-08-13 2004-02-26 Kaneka Corporation Technique d'expression de gene dans des oiseaux transgeniques au moyen de vecteur retroviral et oiseaux transgeniques ainsi obtenus
US6730822B1 (en) 1997-10-16 2004-05-04 Avigenics, Inc. Vectors in avian transgenesis
US7511120B2 (en) 1997-10-16 2009-03-31 Synageva Biopharma Corp. Glycosylated G-CSF obtained from a transgenic chicken
US7534929B2 (en) 1997-10-16 2009-05-19 Synageva Biopharma Corp. Avians expressing heterologous protein
US7803362B2 (en) 2003-01-24 2010-09-28 Synageva Biopharma Corp. Glycosylated interferon alpha
US7812127B2 (en) 2006-03-17 2010-10-12 Synageva Biopharma Corp. Glycosylated human G-CSF
US8124732B2 (en) 2005-06-24 2012-02-28 Synageva Biopharma Corp. Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US8372956B2 (en) 1997-10-16 2013-02-12 Synageva Biopharma Corp. Antibodies produced in a transgenic avian egg white
US8563803B2 (en) 1997-10-16 2013-10-22 Synageva Biopharma Corp. Method of making protein in an egg of a transgenic chicken
CN107182924A (zh) * 2017-06-12 2017-09-22 广西大化桂通农林发展有限公司 一种中鸡的抗病养殖方法
CN107251876A (zh) * 2017-06-12 2017-10-17 广西大化桂通农林发展有限公司 一种中鸡的喂养方法
CN107279050A (zh) * 2017-06-28 2017-10-24 广西大化桂通农林发展有限公司 一种七百弄雏鸡的喂养方法
CN107396877A (zh) * 2017-06-28 2017-11-28 广西大化桂通农林发展有限公司 一种七百弄雏鸡的抗病养殖方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109122550B (zh) * 2018-03-22 2021-02-23 四川省畜牧科学研究院 一种鸡禽白血病净化方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
18th Annual Meeting of UCLA: Symp. Mol. Cell. Biol., J. Cell. Biochem. vol. suppl, no. B, 03 February 1989, page 178 CHEN, H.Y. et al.: "Expression of the bovine Growth Hormone gene in transgenic chickens" *
GENE vol. 38, no. 1-3, 1985, AMSTERDAM NL pages 227 - 232; PASLEAU, F. et al.: "Growth Hormone gene expression in eukaryotic cells directed by the Rous sarcoma virus long terminal repeat or cytomegalovirus immediate-ear ly promoter" *
GENE vol. 76, no. 1, 1989, pages 75 - 80; KELDER, B. et al.: "Aactivation of the mouse methallothionein-I promoter in transiently transfected avian cells" *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698763A (en) * 1991-11-14 1997-12-16 Weissmann; Charles Transgenic animals lacking prion proteins
US7875762B2 (en) 1997-10-16 2011-01-25 Synageva Biopharma Corp. Method of producing an exogenous protein in the egg of a chicken
US8519214B2 (en) 1997-10-16 2013-08-27 Synageva Biopharma Corp. Production of exogenous proteins in egg whites of transgenic chickens
US6730822B1 (en) 1997-10-16 2004-05-04 Avigenics, Inc. Vectors in avian transgenesis
US8563803B2 (en) 1997-10-16 2013-10-22 Synageva Biopharma Corp. Method of making protein in an egg of a transgenic chicken
US7511120B2 (en) 1997-10-16 2009-03-31 Synageva Biopharma Corp. Glycosylated G-CSF obtained from a transgenic chicken
US7521591B2 (en) 1997-10-16 2009-04-21 Synageva Biopharm Corp. Transgenic chickens that lay eggs containing exogenous proteins
US7534929B2 (en) 1997-10-16 2009-05-19 Synageva Biopharma Corp. Avians expressing heterologous protein
US8507749B2 (en) 1997-10-16 2013-08-13 Synageva Biopharma Corp. Transgenic chickens producing exogenous protein in eggs
US8372956B2 (en) 1997-10-16 2013-02-12 Synageva Biopharma Corp. Antibodies produced in a transgenic avian egg white
AU777420B2 (en) * 1999-06-04 2004-10-14 Tranxenogen, Inc. Methods for manipulating the avian genome
WO2000075300A3 (fr) * 1999-06-04 2002-01-10 Tranxenogen Inc Procedes servant a manipuler le genome aviaire
WO2004016081A1 (fr) * 2002-08-13 2004-02-26 Kaneka Corporation Technique d'expression de gene dans des oiseaux transgeniques au moyen de vecteur retroviral et oiseaux transgeniques ainsi obtenus
US7803362B2 (en) 2003-01-24 2010-09-28 Synageva Biopharma Corp. Glycosylated interferon alpha
US8124732B2 (en) 2005-06-24 2012-02-28 Synageva Biopharma Corp. Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US7812127B2 (en) 2006-03-17 2010-10-12 Synageva Biopharma Corp. Glycosylated human G-CSF
CN107182924A (zh) * 2017-06-12 2017-09-22 广西大化桂通农林发展有限公司 一种中鸡的抗病养殖方法
CN107251876A (zh) * 2017-06-12 2017-10-17 广西大化桂通农林发展有限公司 一种中鸡的喂养方法
CN107279050A (zh) * 2017-06-28 2017-10-24 广西大化桂通农林发展有限公司 一种七百弄雏鸡的喂养方法
CN107396877A (zh) * 2017-06-28 2017-11-28 广西大化桂通农林发展有限公司 一种七百弄雏鸡的抗病养殖方法

Also Published As

Publication number Publication date
JPH03210136A (ja) 1991-09-13
CA2027619A1 (fr) 1991-04-17

Similar Documents

Publication Publication Date Title
US4997763A (en) Vectors for gene insertion into avian germ line
US5162215A (en) Method of gene transfer into chickens and other avian species
Sealy et al. Site-specific mutagenesis of avian erythroblastosis virus: erb-B is required for oncogenicity
Bosselman et al. Replication-defective vectors of reticuloendotheliosis virus transduce exogenous genes into somatic stem cells of the unincubated chicken embryo
EP0424044A1 (fr) Poule transgénique exprimant l'hormone de croissance bovine
Petropoulos et al. Appropriate in vivo expression of a muscle-specific promoter by using avian retroviral vectors for gene transfer [corrected]
US6287863B1 (en) Method of transferring a DNA sequence to a cell in vitro
US20090042299A1 (en) Vectors and methods for tissue specific synthesis of proteins in eggs of transgenic hens
JPH04505261A (ja) ポルｉｉｉプロモーターの制御下の転写可能な外来ｄｎａを含む安定的に形質転換された真核細胞
EP0188574A1 (fr) Vaccins et vecteurs retroviraux, et methodes pour leur construction
US20050273872A1 (en) Protein production in transgenic avians
EP0424027A1 (fr) Vecteurs permettant la génération de poule transgénique
HUGHES et al. Design of retroviral vectors for the insertion of foreign deoxyribonucleic acid sequences into the avian germ line
AU6037296A (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US20050022260A1 (en) Method of efficiently constructing transgenic birds and transgenic birds thus obtained
JPH07500490A (ja) 非感染性ｈｉｖゲノムを保持するトランスジェニック非ヒト動物
Salter et al. Avian leukosis retroviruses and gene transfer into the avian genome
US20040172666A1 (en) Transgenic birds and method of producing protein using same
US6936465B1 (en) Plasmid vector comprising a retroviral integrase gene and an integrase recognition region
EP1050586A1 (fr) Procede relatif au transfert de gene dans des cellules germinales
Hippenmeyer et al. Transfer and expression of the bacterial NPT-II gene in chick embryos using a Schmidt-Ruppin retrovirus vector
USH1065H (en) Transgenic avian line resistant to avian leukosis virus
Salter et al. Gene insertion into the avian germline
Finkelstein et al. Live recombinant vaccines for poultry
US20030190753A1 (en) Vectors for gene transfer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI NL

17P Request for examination filed

Effective date: 19910905

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19930722